Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report second quarter 2011 financial results after the NASDAQ Global Select Market closes on Tuesday, August 9, 2011. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the second quarter 2011 and to provide a business and financial update.

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2011 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate is intended for weight management.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication o
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
2. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
3. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
4. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
7. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
9. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
10. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: ... Financial Officer James H. Mackaness is scheduled to ... 2015, at 9:00 am PT in Los Angeles ... presentation may be accessed on the Event Calendar of the ... replay of the webcast will be available shortly after the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... the ASSERT Trial Presented at EULAR, BARCELONA, ... today at the European League Against Rheumatism ... patients with,ankylosing spondylitis (AS) who received REMICADE(R) ... spinal,mobility. In addition, REMICADE-treated patients showed sustained,reductions ...
... from 741-patient trial show those treated with,Prexige experienced ... , * Many patients with osteoarthritis also have ... can impact,cardiovascular risk[2],[3] , * Prexige approved in ... US for use in osteoarthritis patients , BASEL, ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 6
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... 2015 EHO offers a suite of ... gives hospices the ability to manage their drug-spend for ... business model, EHO has been able to compete with ... clients and survive among the giants of the industry. ... three years ago, it has simplified the way hospices ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Cyclist ... tour, “Wheels for the World 2015: Piles of ... to raise awareness about hemophilia and encourage individuals ... Life. , Save One Life supports nearly ... eleven developing countries through direct sponsorships, scholarships and ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a new hanging ... signs ; making what was formerly an elite expensive ... points at a usual height of 16’-20’ are easily seen ... are very unique and more visible than the largest exhibits. ... labor and rigging the costs far outweigh the benefit of ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2
... a medical conference that takes place entirely online, announces participation of ... Prevention Center. Dr. Kaskel to present "Improved Patient Outcomes and ... ... MA (PRWEB) February 18, 2009 -- CardioCareLive , the first ...
... 18 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... company that controls,and operates pharmaceutical companies in ... that contractually controlled Beijing Liang Fang,Pharmaceutical Co., ... rights,transfer contract with Beijing Yipuan Bio-Medical Technology ...
... Has Resisted Well, - Continued Reduction in Net Debt, In millions of euros ... 168.4 ... 19.3 26.8, EBITDA margin ... Current operating income* 4.6 12.0, ...
... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on Chicago ... 6:00 PM on Channel 21. Monday,s program, with ... the Balancing Center in Chicago will discuss the health ...
... Michael J. Fox Foundation for Parkinson,s Research awarded ... to develop neuroimaging technologies that would allow scientists ... protein in the living human brain. Such technologies ... and treatment of PD. Investigators could more accurately ...
... and survival is poorer, new report finds , , WEDNESDAY, ... rates continue to decline, an American Cancer Society report ... more advanced stages of cancer than whites, the report,s ... each stage of diagnosis of most types of cancers. ...
Cached Medicine News:Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 3Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 2Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 3Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 4Health News:PCAS: 2008 Results 2Health News:PCAS: 2008 Results 3Health News:Save Your Money and Your Health 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 3Health News:Cancer Death Rates Decline Among Blacks, But Disparities Linger 2Health News:Cancer Death Rates Decline Among Blacks, But Disparities Linger 3
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
Medicine Products: